182 related articles for article (PubMed ID: 15989538)
1. New and emerging treatments for irritable bowel syndrome and functional dyspepsia.
Talley NJ
Expert Opin Emerg Drugs; 2002 May; 7(1):91-8. PubMed ID: 15989538
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic therapy for the irritable bowel syndrome.
Talley NJ
Am J Gastroenterol; 2003 Apr; 98(4):750-8. PubMed ID: 12738451
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and therapeutic strategies in the irritable bowel syndrome.
Cremonini F; Talley NJ
Minerva Med; 2004 Oct; 95(5):427-41. PubMed ID: 15467518
[TBL] [Abstract][Full Text] [Related]
4. The brain-gut axis in irritable bowel syndrome--clinical aspects.
Mach T
Med Sci Monit; 2004 Jun; 10(6):RA125-31. PubMed ID: 15173682
[TBL] [Abstract][Full Text] [Related]
5. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
Farthing MJ
Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
[TBL] [Abstract][Full Text] [Related]
6. Drug therapy options for patients with irritable bowel syndrome.
Talley NJ
Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
8. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
Moskwa A; Boznańska P
Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
[TBL] [Abstract][Full Text] [Related]
9. Review article: clinical evidence to support current therapies of irritable bowel syndrome.
Camilleri M
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():48-53. PubMed ID: 10429740
[TBL] [Abstract][Full Text] [Related]
10. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
Beglinger C
Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
[TBL] [Abstract][Full Text] [Related]
11. Tegaserod for constipation-predominant irritable bowel syndrome.
Kale-Pradhan PB; Wilhelm SM
Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.
Schoenfeld P
Gastroenterol Clin North Am; 2005 Jun; 34(2):319-35, viii. PubMed ID: 15862938
[TBL] [Abstract][Full Text] [Related]
13. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
[TBL] [Abstract][Full Text] [Related]
14. The spectrum of irritable bowel syndrome: A clinical review.
Gilkin RJ
Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443
[TBL] [Abstract][Full Text] [Related]
15. New developments in the treatment of irritable bowel syndrome.
De Schryver AM; Samsom M
Scand J Gastroenterol Suppl; 2000; (232):38-42. PubMed ID: 11232489
[TBL] [Abstract][Full Text] [Related]
16. Treatment of irritable bowel syndrome.
Trinkley KE; Nahata MC
J Clin Pharm Ther; 2011 Jun; 36(3):275-82. PubMed ID: 21545610
[TBL] [Abstract][Full Text] [Related]
17. Treatment options in irritable bowel syndrome.
Farthing MJ
Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):773-86. PubMed ID: 15324713
[TBL] [Abstract][Full Text] [Related]
18. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
De Ponti F; Tonini M
Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
[TBL] [Abstract][Full Text] [Related]
19. Functional dyspepsia: drugs for new (and old) therapeutic targets.
Cremonini F; Delgado-Aros S; Talley NJ
Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):717-33. PubMed ID: 15324710
[TBL] [Abstract][Full Text] [Related]
20. Tegaserod and other serotonergic agents: what is the evidence?
Chey WD
Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
